[go: up one dir, main page]

AR106141A1 - Métodos e intermediarios para la preparación de derivados de ácidos biliares - Google Patents

Métodos e intermediarios para la preparación de derivados de ácidos biliares

Info

Publication number
AR106141A1
AR106141A1 ARP160102924A ARP160102924A AR106141A1 AR 106141 A1 AR106141 A1 AR 106141A1 AR P160102924 A ARP160102924 A AR P160102924A AR P160102924 A ARP160102924 A AR P160102924A AR 106141 A1 AR106141 A1 AR 106141A1
Authority
AR
Argentina
Prior art keywords
preparation
methods
intermediaries
derivatives
biliary acids
Prior art date
Application number
ARP160102924A
Other languages
English (en)
Inventor
R Iorga Kayla
Chavez Flavio
E Whitley Paul
Schaab Kevin
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of AR106141A1 publication Critical patent/AR106141A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente se refiere a métodos e intermediarios útiles en la preparación de un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, donde R¹ es H o alquilo C₁₋₆.
ARP160102924A 2015-09-24 2016-09-26 Métodos e intermediarios para la preparación de derivados de ácidos biliares AR106141A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562222943P 2015-09-24 2015-09-24

Publications (1)

Publication Number Publication Date
AR106141A1 true AR106141A1 (es) 2017-12-13

Family

ID=58387485

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102924A AR106141A1 (es) 2015-09-24 2016-09-26 Métodos e intermediarios para la preparación de derivados de ácidos biliares

Country Status (13)

Country Link
US (1) US11072631B2 (es)
EP (1) EP3353189A4 (es)
JP (1) JP2018528230A (es)
KR (1) KR20180052756A (es)
CN (1) CN108350020A (es)
AR (1) AR106141A1 (es)
AU (1) AU2016325619A1 (es)
CA (1) CA2999302A1 (es)
HK (1) HK1254057A1 (es)
IL (1) IL258113A (es)
MX (1) MX2018003649A (es)
TW (1) TW201718622A (es)
WO (1) WO2017053826A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1243930A1 (zh) 2014-11-06 2018-07-27 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CA2968404A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2016130809A1 (en) 2015-02-11 2016-08-18 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
SG11201707263XA (en) 2015-03-31 2017-10-30 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
JP2019529481A (ja) * 2016-09-30 2019-10-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁酸誘導体の結晶形態
AU2017368069B2 (en) 2016-11-29 2021-07-08 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
MX388300B (es) 2017-04-07 2025-03-19 Enanta Pharm Inc Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato
EP3660030A4 (en) * 2017-07-26 2021-04-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. METHOD OF MANUFACTURING STEROID-DERIVATIVE FXR AGONISTS
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
EP4041722A4 (en) 2019-10-07 2023-12-13 Kallyope, Inc. GPR119 AGONISTS
BR112022017039A2 (pt) 2020-02-28 2022-11-16 Kallyope Inc Agonistas de gpr40
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216015A (en) * 1991-02-05 1993-06-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having hypocholesterolemic properties
JP4021327B2 (ja) 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Ｆｘｒに対する作用薬としてのステロイド
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
ES2523591T3 (es) 2006-06-27 2014-11-27 Intercept Pharmaceuticals Inc. Derivados de ácidos biliares como ligandos de FXR para la prevención o el tratamiento de enfermedades o estados mediados por FXR
ES2458168T3 (es) * 2008-11-19 2014-04-30 Intercept Pharmaceuticals, Inc. Moduladores de TGR5 y método de uso de los mismos
EP3789394A1 (en) 2012-06-19 2021-03-10 Intercept Pharmaceuticals, Inc. Crystalline forms c of obeticholic acid
CA2889592A1 (en) * 2012-10-26 2014-05-01 Roberto Pellicciari Process for preparing bile acid derivatives
BR112015012312A2 (pt) * 2012-11-28 2017-07-11 Intercept Pharmaceuticals Inc método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito
US20140187633A1 (en) * 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
RS59910B1 (sr) * 2014-05-29 2020-03-31 Bar Pharmaceuticals S R L Derivati holana za upotrebu u lečenju i/ili prevenciji fxr i tgr5/gpbar1 posredovanih bolesti
EP3253382B1 (en) 2015-02-06 2021-11-17 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
CN108137643A (zh) 2015-08-07 2018-06-08 英特塞普特医药品公司 制备胆汁酸及其衍生物的方法
JP6824966B2 (ja) 2015-09-21 2021-02-03 インターセプト ファーマシューティカルズ， インコーポレイテッド 肝臓の再生を促進する方法

Also Published As

Publication number Publication date
IL258113A (en) 2018-05-31
CN108350020A (zh) 2018-07-31
EP3353189A4 (en) 2019-06-19
US20200239515A1 (en) 2020-07-30
EP3353189A1 (en) 2018-08-01
KR20180052756A (ko) 2018-05-18
TW201718622A (zh) 2017-06-01
AU2016325619A1 (en) 2018-04-12
CA2999302A1 (en) 2017-03-30
HK1254057A1 (zh) 2019-07-12
JP2018528230A (ja) 2018-09-27
US11072631B2 (en) 2021-07-27
WO2017053826A1 (en) 2017-03-30
MX2018003649A (es) 2018-05-11

Similar Documents

Publication Publication Date Title
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
AR108768A2 (es) Compuestos de piridina y pirazol y sus usos para la modulación de hemoglobina
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PE20160862A1 (es) Polimorfo de los inhibidores de la syk
EA201692219A1 (ru) Способы получения противовирусных соединений
AR093659A1 (es) Derivados ciclicos de nucleosidos y usos de los mismos
MX2016006199A (es) Inhibidores de replicacion del virus de influenza.
AR113803A1 (es) Compuesto de pirimidina como inhibidor de jak quinasas
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
MA39866A (fr) Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle
MX2015014688A (es) Tiazoles y usos de los mismos.
AR103680A1 (es) Inhibidores selectivos de bace1
MX387483B (es) Preparación farmacéutica.
CU20170007A7 (es) Compuestos de imidazopiridazina
AR095097A1 (es) Compuestos de fenoxietoxi
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
AR095015A1 (es) Compuestos de azetidiniloxifenilpirrolidina
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201891431A1 (ru) Способы получения замещенного 5,6-дигидро-6- фенилбензо[f]изохинолин-2-амина
MX2018012777A (es) Métodos para preparación de ácido obeticólico y derivados de los mismos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure